



## Acceptance Notification: AACR Annual Meeting 2023 in Orlando, Florida

**Title:** Circulating long non-coding RNA HULC as an early indicator of hepatocellular carcinoma irrespective of etiology

Dear Dr. George:

Your above-referenced abstract has been scheduled for presentation in a Poster Session at the AACR Annual Meeting 2023 in Orlando, Florida, and will be published in the online *Proceedings of the AACR*. Presentation information pertaining to your abstract is provided below:

**Session Category:** Clinical Research Excluding Trials

**Session Title:** Early Detection Biomarkers

**Session Date and Time:** Monday Apr 17, 2023 1:30 PM - 5:00 PM

**Location:** Poster Section 42

**Poster Board Number:** 14

**Published Abstract Number:** 3339 [Your abstract will be published and cited with this number. Place this number on your poster board.]

Please review the following important information about your poster presentation:

1. **IMPORTANT: In-Person Presentation.** All proffered papers that are accepted for poster presentation at the AACR Annual Meeting 2023 must be presented in person. Posters will not be presented in electronic format. Presenters who are unable to travel to Orlando to present their poster in person will have the opportunity to designate a coauthor to serve as the presenter. If no coauthors are available to present the paper in person, the abstract must be withdrawn via a written request sent to [abstractchanges@aacr.org](mailto:abstractchanges@aacr.org).
2. **IMPORTANT: Publication of Abstracts in *Cancer Research* Prior to the Annual Meeting.** Beginning in 2023, regular abstracts accepted for presentation at the AACR Annual Meeting will be published in an online-only *Proceedings* supplement to the AACR journal *Cancer Research* prior to the meeting on **Friday, March 31**. Therefore, all requests to withdraw or edit abstracts must be sent to [abstractchanges@aacr.org](mailto:abstractchanges@aacr.org) no later than **5:00 PM ET on Monday, February 20**.
3. **Embargo Information.** Please note that your abstract is under strict embargo. The content of your abstract must be kept confidential until it is made publicly available. In accordance with the AACR's embargo policy, the complete title and text of your regular abstract will be posted to the AACR Online Program Planner at **4:30 PM ET on Tuesday, March 14**. Abstracts that have been selected for inclusion in the AACR press program will be made publicly available at the date and time of presentation, either at the meeting or an official AACR press conference. As indicated above, your abstract will be published in an online-only supplement to the AACR journal *Cancer Research* on Friday, March 31.
4. **Registration and Housing.** Poster presenters must register to attend the AACR Annual Meeting 2023 at the rate appropriate to their membership status and obtain their own hotel accommodations. Registration and housing information are included below:  
**Advance Registration Deadline: Friday, February 24**  
[Online Registration](#)  
  
**Deadline to Make Hotel Reservations: Friday, March 3.** In the event that a wait list is implemented for AACR Annual Meeting 2023 hotels, abstract presenters will be given priority status. Please visit the hotel reservation site below and make your housing request as soon as possible. You will receive a housing confirmation within the next few weeks.  
[Make a Hotel Reservation](#)

5. **Poster Creation/Printing and Delivery Service.** The AACR has partnered with Genigraphics to provide poster printing and onsite delivery services for the AACR Annual Meeting 2023. Presenters are encouraged to take advantage of this simple, convenient way to print their posters and pick them up onsite at the meeting in Orlando. The regular deadline to order poster printing and delivery without paying rush fees is **2:00 PM ET on Friday, March 24**. The rush deadline is 2:00 PM ET on Friday, April 7. While ordering poster printing, you must enter your abstract presentation number (the newly-assigned number that will be published with your abstract). Your abstract presentation number is below:  
**Abstract Presentation Number: 3339** (enter this number into the poster printing order form)  
[Learn More about Poster Printing and Place an Order](#)
6. **Session Format.** Presenters will be admitted to the poster area beginning 30 minutes before the start of each session to hang their posters. Poster sessions last for three and a half hours, and posters must remain on the assigned board for this entire period. Presenters must remain at their posters for only the first two and a half hours. During the final hour presenters are free to examine the other posters or to attend other sessions. Poster materials must be removed immediately at the end of the session; posters left on the boards after sessions will not be saved.
7. **Poster Format.** Poster boards have a usable area of **5.75 feet in width and 3.75 feet in height (approximately 1.75 meters wide and 1.1 meters high)**. Posters should be printed in horizontal (landscape) format. Each presentation should contain a top panel listing the abstract presentation number (provided below), the title of the abstract, and the names of the authors.  
**Abstract Presentation Number: 3339** (place this number on your poster)
8. **Withdrawals.** If you need to withdraw your abstract for any reason, please send a written request to [abstractchanges@aacr.org](mailto:abstractchanges@aacr.org). Withdrawals must be received no later than **5:00 PM ET on Monday, February 20**.

For more information, [visit the AACR Annual Meeting 2023 home page](#).

Thank you for your participation in the AACR Annual Meeting 2023.

Sincerely,  
Robert H. Vonderheide, MD, DPhil  
Program Committee Chair

**Abstract Control Number:** 5766 [This number is for internal reference only; do not place it on your poster.]

PLEASE NOTE: This document is your official notice of acceptance. No separate letter of acceptance will be mailed.

For all login problems or technical questions, please contact [OASIS Helpdesk](#) or call 217-398-1792. If you have policy-related questions, please contact AACR at 215-440-9300 or 866-423-3965.

 Feedback

## ARTICLE NAVIGATION

POSTER PRESENTATIONS - PROFFERED ABSTRACTS | APRIL 04 2023

**Abstract 3339: Circulating long non-coding RNA HULC as an early indicator of hepatocellular carcinoma irrespective of etiology** **FREE**

Joseph George; Mutsumi Tsuchishima; Mikihiro Tsutsumi



Check for updates

[+ Author & Article Information](#)*Cancer Res* (2023) 83 (7\_Supplement): 3339.<https://doi.org/10.1158/1538-7445.AM2023-3339>

Split-Screen

Share ▾

Tools ▾

Versions ▾

## Abstract

**Background:** Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide and is highly prevalent in Asian countries. Long noncoding RNAs (lncRNAs) are non-coding transcripts with a size of more than 200 bases in length. Several studies reported that lncRNAs are highly deregulated in HCC and could be used as biomarkers for early diagnosis and prognostic purposes. In the present study, we measured the circulating lncRNA HULC as an early diagnostic marker for HCC with different etiology.

**Methods:** Serum samples were collected from healthy controls, liver cirrhosis (LC), and HCC patients with different etiology and stored at -80°C until assay. Total RNA was extracted using Qiagen RNeasy kit and tested for RNA quantity and purity using NanoDrop spectrophotometer. The RNA extract that contains lncRNA HULC was transcribed into cDNA using a reverse transcription kit. Employing target specific primers for the lncRNA HULC, qRT-PCR was performed with the synthesized cDNA using Qiagen QuantiFast SYBR Green PCR kit on a Rotor-Gene qRT-PCR system.

**Results:** Quantification of lncRNA HULC using qRT-PCR in the serum samples demonstrated significant increase in LC cases and in all HCC cases irrespective of etiology compared to the normal healthy controls. The highest concentration was observed in serum samples from HCC patients with hepatitis B virus (HBV) infection, which was about 8 fold higher compared to healthy controls. There was no significant difference between the mean HULC lncRNA levels in HCC patients with different etiology such as alcoholic cirrhosis, LC due to other reasons, hepatitis B and hepatitis C virus (HCV) infections, and HCC developed from other unknown causes. However,

serum HULC lncRNA levels in LC cases without HCC was significantly lower compared to all HCC samples.

**Conclusions:** The results of the present study demonstrated that there is a significant increase in HULC lncRNA levels in the serum samples of all HCC patients irrespective of etiology. Therefore, the circulating lncRNA HULC could be used as an early diagnostic biomarker for HCC before appearing other clinical symptoms.

**Citation Format:** Joseph George, Mutsumi Tsuchishima, Mikihiro Tsutsumi. Circulating long non-coding RNA HULC as an early indicator of hepatocellular carcinoma irrespective of etiology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7\_Suppl):Abstract nr 3339.

---

©2023 American Association for Cancer Research

Advertisement

View Metrics

### Citing Articles Via

Google Scholar

[Skip to Main Content](#)